Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ju Yeon | - |
dc.contributor.author | Lee, Hyun Tae | - |
dc.contributor.author | Shin, Woori | - |
dc.contributor.author | Chae, Jongseok | - |
dc.contributor.author | Choi, Jaemo | - |
dc.contributor.author | Kim, Sung Hyun | - |
dc.contributor.author | Lim, Heejin | - |
dc.contributor.author | Heo, Tae Won | - |
dc.contributor.author | Park, Kyeong Young | - |
dc.contributor.author | Ryu, Seong Eon | - |
dc.contributor.author | Son, Ji Young | - |
dc.contributor.author | Lee, Jee Un | - |
dc.contributor.author | Heo, Yong-Seok | - |
dc.date.accessioned | 2021-08-02T16:27:21Z | - |
dc.date.available | 2021-08-02T16:27:21Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/22159 | - |
dc.description.abstract | Cancer cells express tumour-specific antigens derived via genetic and epigenetic alterations, which may be targeted by T-cell-mediated immune responses. However, cancer cells can avoid immune surveillance by suppressing immunity through activation of specific inhibitory signalling pathways, referred to as immune checkpoints. In recent years, the blockade of checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has enabled the development of breakthrough therapies in oncology, and four therapeutic antibodies targeting these checkpoint molecules have been approved by the FDA for the treatment of several types of cancer. Here, we report the crystal structures of checkpoint molecules in complex with the Fab fragments of therapeutic antibodies, including PD-1/pembrolizumab, PD-1/nivolumab, PD-L1/BMS-936559 and CTLA-4/tremelimumab. These complex structures elucidate the precise epitopes of the antibodies and the molecular mechanisms underlying checkpoint blockade, providing useful information for the improvement of monoclonal antibodies capable of attenuating checkpoint signalling for the treatment of cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ryu, Seong Eon | - |
dc.identifier.doi | 10.1038/ncomms13354 | - |
dc.identifier.scopusid | 2-s2.0-84994057015 | - |
dc.identifier.wosid | 000386515200001 | - |
dc.identifier.bibliographicCitation | NATURE COMMUNICATIONS, v.7, pp.1 - 10 | - |
dc.relation.isPartOf | NATURE COMMUNICATIONS | - |
dc.citation.title | NATURE COMMUNICATIONS | - |
dc.citation.volume | 7 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | T-CELL-ACTIVATION | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | B7 FAMILY | - |
dc.subject.keywordPlus | CRYSTAL-STRUCTURE | - |
dc.subject.keywordPlus | CO-STIMULATION | - |
dc.subject.keywordPlus | PD-1 BLOCKADE | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | DEATH 1 | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.identifier.url | https://www.nature.com/articles/ncomms13354 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.